Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Endocrinology & Metabolism
Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin
Summary: The study reported a case of a patient who developed symptomatic primary hypothyroidism after receiving Lu-177-DOTATATE therapy, with notable changes in TFTs and thyroid auto-antibody titers before and after treatment. Functional imaging revealed diffuse uptake of Lu-177-DOTATATE in the thyroid gland.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Ryuhei Okada, Takuya Kato, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Daiki Fujimura, Shuhei Okuyama, Hideyuki Furumoto, Hiroshi Fukushima, Peter L. Choyke, Hisataka Kobayashi
Summary: This study compared the effects of Panitumumab and Cetuximab in APCs for NIR-PIT and the impact of different light exposure regimens on tumor growth in an immunocompetent mouse model. The results showed that APCs with longer half-life and double light exposure had superior outcomes in cancer cell-targeted NIR-PIT.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Pharmacology & Pharmacy
Typhanie Ladriere, Julie Faudemer, Elise Levigoureux, Damien Peyronnet, Cedric Desmonts, Jonathan Vigne
Summary: Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (Lu-177) based radiopharmaceuticals has become a personalized treatment approach in nuclear medicine and oncology. The efficacy of Lu-177 radiopharmaceuticals has been well-reported, but data on patient safety and management are needed. This review focuses on tailored approaches to optimize the risk-benefit trade-off of radioligand therapy using approved Lu-177 based radiopharmaceuticals.
Article
Chemistry, Multidisciplinary
Patrick Cieslik, Manja Kubeil, Kristof Zarschler, Martin Ullrich, Florian Brandt, Karl Anger, Hubert Wadepohl, Klaus Kopka, Michael Bachmann, Jens Pietzsch, Holger Stephan, Peter Comba
Summary: We report a nonadentate bispidine compound that can bind theranostically relevant radionuclides under mild labeling conditions. The compound shows high stability and inertness in human serum, allowing for simultaneous imaging and treatment without changing the type of bioconjugate. The compound, when conjugated to a peptide, can target and treat neuroendocrine tumors. The study also investigates the biodistribution and accumulation pattern in cell lines and mouse models.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2022)
Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Article
Materials Science, Multidisciplinary
Alex Yang-Hao Yu, Ru-Huei Fu, Shan-hui Hsu, Chen-Feng Chiu, Wei-Hsiang Fang, Chun-An Yeh, Cheng-Ming Tang, Hsien-Hsu Hsieh, Huey-Shan Hung
Summary: Utilizing collagen gold nanoparticles as a carrier for EGFR siRNA shows promising results in treating lung cancer, leading to significant tumor suppression effects and improved survival rates.
MATERIALS TODAY ADVANCES
(2021)
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Oncology
Tianyu Zeng, Hai Xu, Yincheng Liu, Chunxiao Sun, Fan Yang, Yan Liang, Xiang Huang, Ziyi Fu, Wei Li, Yongmei Yin
Summary: This study assessed the frequency of lung cancer following breast cancer diagnosis and the associations between the two types of cancer. The results showed that breast cancer patients, especially those with low-grade malignancy, have a higher risk of developing primary lung cancer. Close follow-up is recommended for patients with isolated ground-glass nodules and high-risk factors. Additionally, EGFR may play an important role in primary lung adenocarcinomas and breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Mengkai Yang, Tao Zhang, Yangfeng Zhang, Xiaojun Ma, Jing Han, Ke Zeng, Yafei Jiang, Zongyi Wang, Zhuoying Wang, Jing Xu, Yingqi Hua, Zhengdong Cai, Wei Sun
Summary: The study revealed that MYLK4 promotes the growth and metastasis of osteosarcoma by activating the EGFR signaling pathway. Additionally, the combination of MYLK4 and EGFR inhibitors showed synergistic effects on the growth and metastasis of OS in vitro and in vivo.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Biology
Yongjian Huang, Jana Ognjenovic, Deepti Karandur, Kate Miller, Alan Merk, Sriram Subramaniam, John Kuriyan
Summary: Research has shown that the EGFR receptor can adopt different conformations of the extracellular module when binding to different ligands, with implications for intracellular signaling pathways.
Article
Engineering, Electrical & Electronic
Hooriyeh Sadat Nourbakhsh, Nahid Raoufi, Kobra Omidfar, Mehdi Ardjmand
Summary: In this study, a novel surface-plasmon-resonance (SPR)-based optical biosensor was developed for sensitive detection of epidermal growth factor receptor (EGFR). The sensor was constructed by immobilizing an anti-human EGFR monoclonal antibody (anti-EGFR mAb) on a modified glassy slide with gold nanoparticles (AuNPs) and four layers of graphene oxide [(GO)(4)]. The SPR signal of AuNPs was used as an analytical signal for quantifying EGFR, showing a linear relationship between EGFR concentration and relative absorbance in the range of 0-100 pg/mL, with a detection limit of 0.65 pg/mL. The immunosensor exhibited good sensitivity, selectivity, stability, and reproducibility, and was suitable for direct measurement of EGFR in human blood samples.
IEEE SENSORS JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Fabiola Sciscione, Simon Guillaume, Abil E. Aliev, Declan T. Cook, Hugo Bronstein, Helen C. Hailes, Paul C. Beard, Tammy L. Kalber, Olumide Ogunlade, Alethea B. Tabor
Summary: Semiconducting polymer nanoparticles (SPN) have potential as exogenous contrast agents for photoacoustic imaging (PAI), but require active targeting strategies and effective characterization techniques. This study developed EGFR-targeted SPN using peptide conjugation and a new NMR method. Preliminary experiments indicated ineffective delivery or destabilization of the formulation.
BIOORGANIC & MEDICINAL CHEMISTRY
(2023)
Article
Pharmacology & Pharmacy
Suvadeep Mal, Tiyasa Saha, Asim Halder, Sudhir Kumar Paidesetty, Suvadra Das, Wong Tin Wui, Urmi Chatterji, Partha Roy
Summary: The World Health Organization has identified breast cancer as the most common form of cancer in recent times. Triple negative breast cancer, the deadliest sub-type, is characterized by a high rate of metastasis and poor prognosis due to the lack of progesterone, estrogen, and HER-2 receptors. This study explores the use of flavonoid-conjugated gold nanoparticles as targeted therapeutics against this subtype.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Review
Oncology
Anastasia Alataki, Mitch Dowsett
Summary: Endocrine therapies are the main treatment for hormone-dependent breast cancer, but HER2 signaling contributes to resistance and affects treatment efficacy. HER2 overexpression plays a role in resistance to endocrine therapies in breast cancer patients, impacting their clinical outcomes.
ENDOCRINE-RELATED CANCER
(2022)
Letter
Oncology
Jean-Philippe Pignol, Nienke Hoekstra
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
G. N. Marta, D. Ramiah, O. Kaidar-Person, A. Kirby, C. Coles, R. Jagsi, T. Hijal, G. Sancho, Y. Zissiadis, J-P Pignol, A. Y. Ho, S. H-C Cheng, B. Offersen, I Meattini, P. Poortmans
Summary: This study evaluated the financial impact of moderately hypofractionated breast irradiation in different countries, finding that financial loss for healthcare providers induced by fee-for-service remuneration may hinder the widespread adoption of these regimens. It is suggested that an alternative system of remuneration, such as bundled payments based on stage and diagnosis, may provide more value for all stakeholders.
Review
Oncology
Gustavo Nader Marta, Charlotte Coles, Orit Kaidar-Person, Icro Meattini, Tarek Hijal, Yvonne Zissiadis, Jean-Philippe Pignol, Duvern Ramiah, Alice Y. Ho, Skye Hung-Chun Cheng, Gemma Sancho, Birgitte Vrou Offersen, Philip Poortmans
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2020)
Article
Biology
Zhongli Cai, Noor Al-saden, Constantine J. Georgiou, Raymond M. Reilly
Summary: The reliability of modeling cellular S-values for AE emitters and their relative dose deposition in subcellular targets were examined using MCNP6. Results showed that Hg-197 and Hg-197m deposit two-fold more doses than In-111 at the subcellular scale. All AE emitters deposit a higher self-dose in cellular and nuclear membranes compared to the nucleus.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
E. Fleury, P. Trnkova, E. Erdal, M. Hassan, B. Stoel, M. Jaarma-Coes, G. Luyten, J. Herault, A. Webb, J-W Beenakker, J-P Pignol, M. Hoogeman
Summary: The study aimed to develop a high-resolution 3D MRI-based treatment planning approach for uveal melanomas, successfully tested on a cohort of eight patients. Target coverage and optimal sparing of OARs were achieved through simulations of various gazing angles and dose optimizations.
Review
Radiology, Nuclear Medicine & Medical Imaging
Ricardo Otazo, Philippe Lambin, Jean-Philippe Pignol, Mark E. Ladd, Heinz-Peter Schlemmer, Michael Baumann, Hedvig Hricak
Summary: MRI-guided RT has become an important tool in cancer treatment, offering superior soft-tissue contrast and the ability to monitor tissue physiologic changes. Institutions are already using offline MRI for treatment planning, and MRI-guided linear accelerator systems allow the use of MRI during treatment, providing better adaptation to anatomic changes. Challenges in advancing MRI-guided RT include real-time volumetric anatomic imaging, image distortion due to magnetic field inhomogeneities, reproducible quantitative imaging, and biological validation of quantitative imaging.
Article
Oncology
Roxanne Gal, Sanne G. M. van Velzen, Maartje J. Hooning, Marleen J. Emaus, Femke van der Leij, Madelijn L. Gregorowitsch, Erwin L. A. Blezer, Sofie A. M. Gernaat, Nikolas Lessmann, Margriet G. A. Sattler, Tim Leiner, Pim A. de Jong, Arco J. Teske, Janneke Verloop, Joan J. Penninkhof, Ilonca Vaartjes, Hanneke Meijer, Julia J. van Tol-Geerdink, Jean-Philippe Pignol, Desiree H. J. G. van den Bongard, Ivana Isgum, Helena M. Verkooijen
Summary: This study found an association between coronary artery calcium (CAC) levels on breast cancer radiotherapy planning CT scans and cardiovascular disease, especially coronary artery disease (CAD). Automated CAC scoring may serve as a quick, cost-effective tool to identify breast cancer patients at increased risk of CVD, enabling the implementation of risk-mitigating strategies to reduce CVD burden after breast cancer.
Review
Oncology
Hannah M. Dahn, Liesbeth J. Boersma, Dirk de Ruysscher, Icro Meattini, Birgitte Offersen, Jean-Philippe Pignol, Cynthia Aristei, Yazid Belkacemi, Dori Benjamin, Nuran Bese, Charlotte E. Coles, Pierfrancesco Franco, Alice Ho, Sandra Hol, Reshma Jagsi, Anna M. Kirby, Livia Marrazzo, Gustavo N. Marta, Meena S. Moran, Alan M. Nichol, Henrik D. Nissen, Vratislav Strnad, Yvonne E. Zissiadis, Philip Poortmans, Orit Kaidar-Person
Summary: The use of bolus in post mastectomy radiation therapy (PMRT) may increase the rate of acute grade 3 radiation dermatitis, but does not appear to significantly impact local recurrence rates compared to not using bolus. Further research is needed to determine the specific cases where bolus may be beneficial in PMRT.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Emmanuelle Fleury, Petra Trnkova, Kees Spruijt, Joel Herault, Franciska Lebbink, Jens Heufelder, Jan Hrbacek, Tomasz Horwacik, Tomasz Kajdrowicz, Andrea Denker, Anais Gerard, Petter Hofverberg, Maria Mamalui, Roelf Slopsema, Jean-Philippe Pignol, Mischa Hoogeman
Summary: Eye-dedicated proton therapy facilities are used to treat malignant intraocular lesions, with the new eyeline from HollandPTC being analyzed in comparison to five other facilities. Differences in nozzle design, nominal energy, and energy spectrum were identified among the centers. Depth dose distributions and treatment time were compared, showing variations in tumor control and potential toxicities among institutions offering eye-dedicated proton therapy.
Article
Oncology
Nienke Hoekstra, Steven Habraken, Annemarie Swaak-Kragten, Mischa Hoogeman, Jean-Philippe Pignol
Summary: In this study, APBI treatment fractions on Cyberknife were assessed to determine that the margin needed to compensate for intrafraction motion increased with longer fraction durations due to drifting of the target. Breathing motion has a limited effect on margin adjustments.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Valerie J. Facca, Zhongli Cai, Nakita E. K. Gopal, Raymond M. Reilly
Summary: The study investigated the use of anti-EGFR panitumumab labeled with 111In for SPECT/CT imaging and radioimmunotherapy of triple-negative breast cancer (TNBC). The results showed that panitumumab-DOTA-In-111 is a promising theranostic agent for TNBC, and combining it with radiosensitizing PARP inhibitors may provide a more durable response to therapy.
MOLECULAR PHARMACEUTICS
(2022)
Article
Medicine, Research & Experimental
Zhongli Cai, Rella Liu, Conrad Chan, Yijie Lu, Mitchell A. Winnik, David W. Cescon, Raymond M. Reilly
Summary: In this study, a novel nanoparticle depot (NPD) brachytherapy seed was used to inhibit the growth of murine mammary carcinoma tumors in mice. The NPD seed incorporated gold nanoparticles (AuNPs) labeled with Y-90, a beta-particle emitting radionuclide. The treatment was effective in inhibiting the growth of the primary tumor and inducing an abscopal effect on a distant non-irradiated tumor, especially when combined with anti-PD-L1 immune checkpoint antibodies.
MOLECULAR PHARMACEUTICS
(2022)
Article
Medicine, Research & Experimental
Valerie J. Facca, Zhongli Cai, Anthony Ku, Constantine J. Georgiou, Raymond M. Reilly
Summary: This study investigated the effectiveness of RIT using [In-111]In-DOTA-panitumumab in combination with tumor resection and XRT for the survival of mice with recurrent TNBC. The results showed that this treatment significantly improved the survival time of the mice.
MOLECULAR PHARMACEUTICS
(2023)
Article
Chemistry, Medicinal
Anthony Ku, Misaki Kondo, Zhongli Cai, Jalna Meens, Min Rong Li, Laurie Ailles, Raymond M. Reilly
Summary: The study assessed the feasibility of a theranostic strategy using [Cu-64]Cu-DOTA-panitumumab F(ab')(2) for imaging HNSCC tumors and predicting radiation doses from RIT with [Lu-177]Lu-DOTA-panitumumab F(ab')(2). Results showed promising potential for RIT in HNSCC treatment, highlighting the need for further research to confirm the findings.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2021)
Meeting Abstract
Oncology
R. Gal, S. G. van Velzen, M. J. Emaus, D. H. van den Bongard, M. L. Gregorowitsch, E. L. Blezer, G. Sofie, N. Lessmann, M. G. Sattler, M. J. Hooning, A. J. Teske, J. J. Penninkhof, H. Meijer, J. P. Pignol, J. Verloop, I. Isgum, H. M. Verkooijen
EUROPEAN JOURNAL OF CANCER
(2020)